Decoding the Microenvironment

Cypre’s human-derived tumor models generate high-resolution insights into mechanism of action and biomarker response—accelerating smarter, FDA-aligned decisions in cancer drug development.
Partner with UsExplore Strategic Access

Why the Microenvironment Matters

Drug developers face increasing pressure to reduce animal studies while improving clinical predictability. Cypre's tumor microenvironment platform, built on our proprietary VersaGel® hydrogel, addresses both. Our organoid models incorporate human tumor, stromal, and immune compartments within a tunable extracellular matrix, generating data that bridges in vitro experiments and human biology.

Unlock Translational Power with a True 3-Tiered Tumor Model

Cypre’s 3D tumor models uniquely integrate tumor, stromal, and immune compartments—recreating the human tumor microenvironment with unmatched fidelity. Built inside our tunable hydrogel matrix, each assay offers mechanistic clarity, faster insights, and more predictive data to accelerate oncology innovation.

Tumor Core: Genomically
Annotated, Patient-Derived

Stromal Layer: Human Fibroblasts + ECM Structure

Phenotypic readouts of T cells, macrophages, 
NK cells, B cells

Start Your Project

Partnering

Cypre partners with pharma and biotech teams to generate mechanistic and biomarker insights earlier in development. Our platform supports programs from target validation through IND-enabling studies, with data designed to inform indication selection and positioning.
Cypre partners with pharma and biotech teams to generate mechanistic and biomarker insights earlier in development. Our platform supports programs from target validation through IND-enabling studies, with data designed to inform indication selection and positioning.
Explore Partnership Opportunities

How We Partner

Cypre offers two distinct collaboration models designed to accelerate oncology innovation—whether you're advancing a lead candidate or building from the ground up.
01

Translational Research

Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. IND-ready data packages support your decision-making and discussions with regulatory agencies.

02

Drug Discovery Partnerships

Selective partnerships based on a multi-target or multi-year framework, spanning target identification, lead development and candidate selection. This integrated approach is designed to efficiently drive lead candidates to IND-enabling studies within two years, using Cypre's human-relevant data at each step.

01

Translational Research

Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. IND-ready data packages support your decision-making and discussions with regulatory agencies.

02

Drug Discovery Partnerships

Selective partnerships based on a multi-target or multi-year framework, spanning target identification, lead development and candidate selection. This integrated approach is designed to efficiently drive lead candidates to IND-enabling studies within two years, using Cypre's human-relevant data at each step.

01

Translational Research

Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. IND-ready data packages support your decision-making and discussions with regulatory agencies.

02

Drug Discovery Partnerships

Selective partnerships based on a multi-target or multi-year framework, spanning target identification, lead development and candidate selection. This integrated approach is designed to efficiently drive lead candidates to IND-enabling studies within two years, using Cypre's human-relevant data at each step.

The Cypre Tumor microenvironment (TME) organoid platform

As global regulatory standards evolve and scrutiny on animal studies intensifies, drug developers need solutions that go further. Cypre’s 3D tumor modeling platform—anchored by our proprietary Symphony® and VersaGel® hydrogel technology—offers a new path forward. By engineering organoids that authentically recapitulate the tumor microenvironment, complete with stromal, extracellular matrix, and immune components, we deliver data with a level of physiological relevance that bridges the gap between in vitro experiments and in vivo outcomes.

How We Help Target Audience Achieve Result

ADCs

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

T cell engagers

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

immunotherapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

targeted therapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

combination

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

Recent Publications

View all
Featured Resources

2025 AACR

At AACR this year, we debuted new datasets on NK cell therapy screening and MOA assessment on the Cypre Tumor Organoid Platform. Post-FDA's announcement, organoids and AI-enabled platforms were a highlight at the conference for Cypre, among an abundance of therapeutic data and precision medicine initiatives.

Featured Resources

2024 Antibody Engineering & Therapeutics

We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data’s implications for cytokine release syndrome.

Featured Resources

2024 AACR Poster

Cypre presented its poster at AACR24: “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703).

View all

Partner with Cypre

Partner with Cypre to generate high-content, human-relevant data using our complete 3D tumor organoids. Designed for fast turnaround, regulatory alignment, and translational decision-making.
Explore Strategic Access
Quick links
Platform
Our Team
Contact
About
Company
Resources & Publications
News & Events
Office:
135 Mississippi Street
San Francisco, CA, 94107
United States
© Cypre Inc. All rights reserved.
Privacy Policy
Terms of Service